About us
Our Team
Jesús Cuervo Uría
Jesús Cuervo holds a degree in Psychology, MSc in Clinical Psychology, in Pharmacoeconomics and Patient Reported Outcomes, and PhD in Health Sciences.

He is the former Scientific Director of Patient Centered Outcomes at Analytica LASER in Spain and has over 13 years’ experience in Health Outcomes Research for Market Access and P&R (at both International and National levels).

Trained in the design of clinical research, psychometrics (qualitative and quantitative methods) and in advance statistical models, Dr. Cuervo is proficiency in developing outcomes research, RWE & value assessment to robustly support MA centred strategies. During his career he has built an strong MA network in key EU markets. Besides, due to his background, he has a proven leadership in patient engagement and in leveraging HTA and MA action plans by stablishing trusted collaborations with multiple stakeholders.

As a PRO expert, he has completed the full development and the transcultural adaptation of multiple questionnaires to assess patients’ Health-Related Quality of Life (HRQoL) and other endpoints in a wide range of pathologies: neurological, oncological, psychiatric, dermatological, pulmonary, cardiovascular, urological and rare diseases. In addition, as an international consultant, he has being involved in the design and implementation of Multi-Criteria Decision Analysis (MCDA) for preference elicitation and the facilitation of informed & shared decision-making.

Finally, Dr. Cuervo has worked on the development & adaptation into Spain of multiple pharmacoeconomic models for renal, oncological, infectious, cardiovascular, rare diseases and medical devices and is the author of multiple manuscripts in peer-review journals.
Carlos Crespo Palomo
Carlos Crespo Palomo holds a PhD in Statistics from the University of Barcelona and He is an Health Economics Expert. He holds a Master in Advanced Studies in Statistics from the University of Barcelona, ??Master's Business Administration by ESADE Business School (5th best European Business School and 1st Spanish by Financial Times) and Master in Health Economics and Health Management from Pompeu Fabra University.

He also holds a degree in Research and Market Techniques from the University of Barcelona and a Bachelor of Science in Statistics from the Polytechnic University of Catalonia, a specialist in the field of healthcare. He has held different management responsibilities, both in the field of health consulting and in market research companies and in the pharmaceutical industry. He has also developed consultancy work for various health corporations, coordinated projects of strategy, efficiency improvement, scorecards, market access, etc. in the field of health, pharmaceutical and public administration.

He is founder & CEO of Axentiva Solutions and He is also an adjunct professor at the University of Barcelona and maintains his academic relationship with the Center for Research in Economics and Health (CRES) at Pompeu Fabra University. Reference speaker and author of scientific articles published in international journals.
Juan Manuel Ramos Goñi
Juan Manuel Ramos Goñi holds a degree in Sciences and Statistics from the University of La Laguna where he took doctoral courses in Statistics and Operational Research, Master in Socio-health Research by the University of Castilla La Mancha, is currently a doctoral candidate in the Erasmus University of Rotterdam. He has held an academic stay at Oxford University (Sep 2009-Dec 2010). He has also taken specific courses in economic evaluation at the Universities of York, Oxford, Birmingham and Cambridge.

He is currently Senior Scientist in the office of EuroQol Research Foundation (since March 2013) and founder of Axentiva. He has held various positions in the administration both in statistical institutes and in health services, especially notable is the experience in HTA services, specifically in economic evaluation. He has also carried out consultancy work for various health corporations, in the area of ??health and pharmaceutical companies, mainly by carrying out economic evaluation models, but also more recently collaborated with universities (UCLM, LSE, Erasmus) in the application of multicriteria decision analysis (MCDA).

In addition, it has developed the tariff of the EQ-5D-5L in Spain and has collaborated in the development of the tariff for multiple countries, such as Uruguay, Hong Kong, Indonesia, ...
Mark Oppe
Mark Oppe holds an MSc in astrophysics from Utrecht University and a PhD in health economics from Erasmus University Rotterdam. He has been working as a health economics researcher for 17 years and has more than 40 publications in various international peer reviewed journals.
He started as a health economics researcher at the Centre for Health Policy and Law of Erasmus University Rotterdam and as statistician for the Dutch renal registry Renine. From 2005 to 2012 he worked at the institute for Medical Technology Assessment (iMTA) at Erasmus University Rotterdam focusing on quantitative research related to economic evaluations in addition to teaching and various consultancy projects for industry.
From 2002 to 2018 Mark worked at the office of the EuroQol Research Foundation where his work focused on methods for developing value sets for the EQ-5D. He was the lead developer of the EQ-VT, the standardised study protocol for obtaining EQ-5D-5L value sets and has supported valuation studies in more than 20 countries. From 2015 to 2018 he was the chair of the Descriptive Systems Working Group of the EuroQol Research Foundation, setting up and managing a multinational research programme.
Mark is a founding member of the International Academy of Health Preference Research (IAHPR) and external affiliate of the Erasmus Choice Modelling Centre (ECMC).
+ 15 years working for the pharmaceutical industry developing market access strategies and health economics tools.
HTA Bodies
Member of Canary Island Health Technology Assessment during 6 years.
Pharmaceutical Industry
Former Director in a Big pharma with experience of put on the market innovative drugs.
Member of an international research group (EuroQol), and former collaborating experts in FP7 and Horizon2020 Programmes.
University teacher and visiting professor in international and national post-graduate courses & programs in Health Economics and Market Access.
Would you like to know more about us?